aprepitant oral / Generic mfg. - LARVOL DELTA

Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Rabin Medical Center

Checkpoint inhibition • New P1 trial • Dermatology • Oncology • Pruritus • Solid Tumor

APRE-PONV: Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: IWK Health Centre | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2026 ➔ Sep 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Enrollment open • Trial completion date • Trial primary completion date • Anesthesia

HN-PONV-ADR-01: Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer (clinicaltrials.gov) - P4 | N=600 | Completed | Sponsor: The First Affiliated Hospital of Zhengzhou University | Not yet recruiting ➔ Completed | Phase classification: PN/A ➔ P4 | Trial completion date: Jul 2025 ➔ Jan 2025 | Initiation date: Dec 2024 ➔ Jul 2024 | Trial primary completion date: May 2025 ➔ Dec 2024

Monotherapy • Phase classification • Trial completion • Trial completion date • Trial initiation date • Trial primary completion date • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Efficacy and safety of aprepitant capsules combined with immunochemotherapy for advanced non-small cell lung cancer. (ChiCTR) - P=N/A | N=110 | Sponsor: Huai'an First People's Hospital; Huai'an First People's Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Patient reported outcomes with use of orally administered aprepitant in highly and moderately emetogenic (HEC and MEC) regimens (ESMO Asia 2024) - "Background NK-1 receptor antagonist aprepitant orally is given over 3 days in HEC and MEC regimens...Though administration of aprepitant provides 100% control of nausea and vomiting, real world practice data suggests otherwise. With narrowing gap in the costs of oral and i.v formulations of aprepitant, the latter must be preferred in HEC and MEC regimens to improve quality of chemotherapy delivery."

Clinical • Patient reported outcomes • Gastrointestinal Cancer • Oncology

A prospective observational study to compare the antiemetic efficacy of fosnetupitant + palonosetron vs oral aprepitant + palonosetron (ESMO Asia 2024) - "Conclusions Patients receiving FP had statistically significant lesser number of events compared to AP. With increasing access to FP, the combination must be the preferred anti-emetic regimen in HEC and MEC regimens."

Clinical • Observational data • Oncology

Comparison of Aprepitant 80mg PO 324mg IV 75mg IV in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Sleeve Gastrectomy (ASHP 2024) - No abstract available

Clinical • Gastrointestinal Disorder

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer (clinicaltrials.gov) - P=N/A | N=600 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Zhengzhou University

Monotherapy • New trial • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Aprepitant mitigates paclitaxel-induced neuropathic pain in rats via suppressing inflammatory pathways in dorsal root ganglia. (PubMed, Drug Chem Toxicol) - "Aprepitant was orally administered every alternate day between days 2 and 14, with a prescribed dosage of 10 or 20 mg/kg. In addition, aprepitant application suppressed the protein expression of NF-kB in the dorsal root ganglia of paclitaxel-treated rats, as revealed by western blot analysis. Aprepitant treatment ameliorates neuropathy induced by paclitaxel, which is associated with decreasing proinflammatory cytokines and NF-kB expression."

Journal • Preclinical • Neuralgia • Oncology • Pain • IL1B • NFKB1 • TNFA

An exploratory study of the efficacy and safety of aprepitant and ondansetron alone or in combination in the prevention of nausea and vomiting after thyroid cancer surgery (ChiCTR) - P4 | N=600 | Not yet recruiting | Sponsor: First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University

New P4 trial • Surgery • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

A Quality Improvement Project: The ERAS Protocol Reduces Post Endoscopic Bariatric Procedure Healthcare Utilization (ACG 2024) - "Before 2019, patients received post-procedure prescriptions for PO ondansentron, promethazine suppositories, PO pantoprazole, PO acetaminophen and PO opiate for breakthrough pain. In 2019, all patients received a standardized peri-procedure hydration, anti-emetic, and analgesic bundle consisting of intravenous fluids, dexamethasone, ondansentron, acetaminophen, ketorolac, pantoprazole, along with a scopolamine patch and oral aprepitant, the " E nhanced R ecovery A fter Endoscopic Procedure S" (ERAS) protocol... 435 endoscopic bariatric procedures were performed between Jan 2012 and March 2022. The mean age of overall group was 51.1 ± 11.3 and 78.2% were female. N=217 procedures were performed before "ERAS" protocol and N=218 were performed with the protocol in place."

Clinical • HEOR • Pain

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (clinicaltrials.gov) - P3 | N=2500 | Recruiting | Sponsor: Jennifer Holder-Murray | Trial completion date: Dec 2025 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date

Efficacy and Safety of a Dexamethasone-Free Antiemetic Regimen for Nausea and Emesis Prevention during Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC (ASTRO 2024) - P2 | "Purpose/Objective(s): The superiority of the triple antiemetic regimen of aprepitant, dexamethasone and ondansetron has been proved in our previous study (NCT03572829), in which the complete remission rate achieved 86% and and the incidence of no vomiting was 88.4%...All patients received aprepitant orally at a dose of 125 mg on day 1, followed by 80mg on days 2-3, palonosetron 0.25 mg on day 1; and olanzapine 5 mg daily on days 1-5... The triple regimen comprising aprepitant, palonosetron and olanzapine effectively prevented nausea and emesis in LA-HNSCC patients undergoing radiotherapy and concomitant high-dose cisplatin chemotherapy, while also reducing the incidence of dexamethasone-induced hiccups. Randomized phase 3 trials are warranted to elucidate the potential role of this combination in chemoradiotherapy setting."

Clinical • Metastases • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Efficacy of aprepitant combined with dual antiemetics in preventing postoperative nausea and vomiting after sleeve gastrectomy: A single-center, randomized controlled trial (ChiCTR) - P=N/A | N=276 | Recruiting | Sponsor: Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University; Nanjing Drum Tower Hospital, Affiliated Hospital of Medical Sc

New trial • Gastrointestinal Disorder

A Study to Evaluate in Patients With Parkinsonian Type Disorders (clinicaltrials.gov) - P2 | N=24 | Active, not recruiting | Sponsor: Chase Therapeutics Corporation | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

APHOS 3: EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: University Hospital, Rouen

New P2 trial • Cardiovascular • Hypertension • Obstructive Sleep Apnea • Pulmonary Arterial Hypertension • Respiratory Diseases • Sleep Disorder

PVP/aprepitant microcapsules produced by supercritical antisolvent process. (PubMed, Sci Rep) - "The results revealed that the APR drug dissolution of the microcapsules by SAS process was faster than the unprocessed APR. Furthermore, the drug powder collected every hour is in the kilogram level, verifying the possibility to scale up the production of pharmaceuticals employing the SAS process from an industrial point of view."

Journal

Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: IWK Health Centre

New P2 trial • Surgery • Anesthesia

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade (clinicaltrials.gov) - P=N/A | N=98 | Recruiting | Sponsor: Hubei Cancer Hospital | Not yet recruiting ➔ Recruiting

Enrollment open

The Effect of Music Therapy on Nausea, Vomiting and Anxiety Levels in Children (clinicaltrials.gov) - P=N/A | N=80 | Not yet recruiting | Sponsor: Bilecik Seyh Edebali Universitesi

New trial • Mood Disorders • Oncology • Psychiatry

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan (clinicaltrials.gov) - P3 | N=52 | Completed | Sponsor: Rush University Medical Center | N=429 ➔ 52

Enrollment change • Bone Marrow Transplantation • Transplantation

NCCN has published updates to the following NCCN Harmonized Guidelines for Sub-Saharan Africa: Antiemesis, Version 2.2023 (NCCN)

NCCN guideline • Chemotherapy-Induced Nausea and Vomiting

Assessing the impact of aprepitant and ondansetron on postoperative nausea and vomiting in orthognathic surgeries: a randomized controlled trial. (PubMed, BMC Anesthesiol) - "According to the findings of this study, aprepitant has demonstrated a greater efficacy in preventing PONV following orthognathic surgery, when compared to ondansetron."

Journal • Surgery • Anesthesia

Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (clinicaltrials.gov) - P3 | N=2500 | Recruiting | Sponsor: Jennifer Holder-Murray | N=35485 ➔ 2500

Enrollment change

Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade (clinicaltrials.gov) - P=N/A | N=98 | Not yet recruiting | Sponsor: Hubei Cancer Hospital

New trial